Skip to main content
Fig. 2 | BMC Ophthalmology

Fig. 2

From: Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

Fig. 2

Anterior segment photographs of patients on vandetanib and osimertinib. Corneal photographs of case 2 taken at 419 days after the start of chemotherapy with vandetanib. a Both corneas showed dense cornea verticillata on the central part (yellow arrows Δ). b Under fluorescein staining, no corneal epithelial defects were found. Corneal photographs of case 4 taken at 305 days after start of chemotherapy with osimertinib. c Vortex keratopathy with a whorl-like pattern was prominent, especially on the patient’s right cornea (yellow arrows Δ). d Under fluorescein staining, no corneal epithelial defects were found

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us